• Be Plus Pro Advanced

    Safety for me

    Safety for patient

    Safety for data

    Non-stop services for community

    WI/FI

  • STM 9000

    ---

    Powerful new generation magnetic stimulator developed on multiprocessor technology with programmable stimulation morphology.

    Butterfly Coil

  • NetBrain 9000

    ---

    Advanced neuronavigation system designed to map brain areas and to support the operator during TMS and rTMS sessions.


  • 1
  • 2
  • 3
  • 4

NEWS & EVENTS

  • Default
  • Title
  • Date
  • Random
  • Default
  • Title
  • Date
  • Random

ABOUT US

EB Neuro in the world

155

Countries

24,248

Products Sold

Founded in 1864, the scientific instruments industry Officine Galileo established, during the 50’s, a new Neurodiagnostic Division, the first in Italy. During the 80’s it became an independent company named ESAOTE and in 1998 a branch of it joined a company named BASIS establishing EB Neuro, a new industrial subject only devoted to Neurodiagnostic. Actually EB Neuro, privately owned, is one of the main worldwide players in the

Neurodiagnostic market both with its own brand and with OEM products. In 2012, EB Neuro expanded its product portfolio through a company fusion with another Italian company of the same market segment named ATES Medica Device.

Thanks to a great cooperation with relevant research organizations and Key Opinion Leaders, EB Neuro wants to further develop its traditional leading role in the innovation of new technologies for EEG/LTM, EMG/EP, Magnetic Transcranial Stimulation and Cardiology.

MAMEM

 

Consortium

 

Greece
The Centre for Research & Technology Hellas is the project coordinator responsible for the administrative, financial and technical management of the project. Its main responsibilities include, translating into meaningful control the EEG-signals captured from the brain of people with disabilities. Moreover, CERTH-ITI is also responsible for the dissemination and exploitation activities of the project with an overarching goal to foster innovation among its members.
Germany
University of Koblenz – Landau, WeST Institute is leading the WP3 and contributes primarily its eye tracking expertise and competence in human-computer interaction.
Italy
EB Neuro S.p.A (EBN) is leading WP2 –“Sensor configuration and signal capturing” with the aim to ensure that the signals delivered to WP3 for translation into meaningful control are properly calibrated and free of any biological or environmental noise. EBN will safeguard that the signal captured in WP2 will be appropriate for the navigation control of a software application. Finally, EBN will significantly contribute in fostering the innovation potential of the technologies developed in MAMEM based on its marketing department.
Germany
As a developer and supplier of eye tracking hardware and software solutions, SensoMotoric Instruments GmbH (SMI) will lead WP4 on combining MAMEM’s sensors and algorithms under a unified re-usable framework. SMI will also actively contribute in optimizing the eye-tracking equipment to the particularities of the cases addressed in MAMEM, as well as on improving the accuracy of gaze-based interaction combined with bio-input.
The Netherlands
Eindhoven University of Technology (TUe) will lead WP5 and based on its large expertise on user modelling and persuasive technology (together with specialists on the specific user group) will describe user models, & persuasive design principles most effectively. This will include coordinating research activities, partly by participants in this WP (Ukob, AUTH) on the effectiveness of prototypes employing these principles, and supervising the actual field tests and lab experiments.
Greece
In MAMEM, Muscular Dystrophy Association (MDA) Hellas will be responsible for the coordination of the pilot studies related to people with neuromuscular disease. The heaviest incidents will be selected to participate in the pilot studies following the protocol defined in WP6. Moreover, MDA Hellas will also lead the work package related to monitoring any changes in the level of the patient’s social inclusion as a result of using MAMEM’s technology.
Greece
In MAMEM, the 3rd Department of Neurology of the Aristotle University of Thessaloniki will recruit Parkinson’s disease patients that fulfill the inclusion criteria to be involved in the project. Moreover, it will be responsible for the clinical evaluation of motor and cognitive function of the patients. Patients will be assessed by means of the Unified Parkinson Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale (UDysRS), the Hoehn &Yahr Stage, the Mini Mental State Examination (MMSE), the Mattis Dementia Rating Scale and the 39-item Parkinson’s Disease Questionnaire.
Israel
The Medical Research Infrastructure Development & Health Services Fund by the Sheba Medical Center (SMC) – (SHEBA), under CATR, will be the scientific coordinator of the ‘clinical’ work package (WP6) of the project. During the development process of MAMEM the SHEBA staff will provide clinical input from expert health professionals as well as technical input regarding the integration of external sensors of MAMEM to subjects with high spinal cord injury. Thus, SHEBA will be in charge for carrying-out the usability & validation clinical studies and coordinate them between all clinical centers.

 

The Project

 

MAMEM’s overarching goal is to integrate people with disabilities back into society by endowing them with the critical skill of managing and authoring multimedia content using novel and more natural interface channels. These channels will be controlled by eye-movements and mental commands, significantly increasing the potential for communication and exchange in leisure (e.g. social networks) and non-leisure context (e.g. workplace).

Its cardinal objective is to facilitate the development of brain-computer interfaces that will lie between the disabled and the conventional interface of a software application dealing with multimedia content. These interfaces will be operated with an eye tracker, an Electroencephalography (EEG) recorder and additional bio-sensors (e.g., heart rate, galvanic skin response).

 

Publications

 

Innovation

The R&D sites in Florence and Colognola ai Colli (VR) represent two centres of excellence, historically and universally recognized in the field of diagnostic sector.

Quality

The quality management system, structured according to ISO 9001 and ISO 13485, is the instrument with which EB Neuro pursues the continuous improvement of its processes, products and services.

Security

The attention to safety allows to maintain high quality standards, recognized by the certifications for which we are qualified (CE marking according to Regulation (EU) 2017/745 (MDR) or Directive 93/42/EEC (MDD)).

Support

Highly qualified service, in terms of technical and specialist assistance, remotely and "on site", for hardware and software installation, configuration of devices and peripherals, optimization of software procedures.

Contacts

Support

Work with Us

Policy

Research Projects